AstraZeneca (AZN) News Today £107.94 -193.31 (-1.76%) As of 11:54 AM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainability All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period AZN INVESTOR ALERT: AstraZeneca PLC Investors with Substantial Losses Have Opportunity to Lead Investor Class Action LawsuitJanuary 17 at 10:09 PM | markets.businessinsider.comAstraZeneca lymphoma therapy Calquence gets expanded approval in the U.S.January 17 at 5:08 PM | msn.comGuggenheim lifts AstraZeneca stock target, buy rating on prospectsJanuary 17 at 5:08 PM | msn.comAstraZeneca said to have changed management of its China unitJanuary 17 at 5:08 PM | msn.comAstraZeneca's Dato-DXd BLA accepted for priority reviewJanuary 13, 2025 | msn.comAstraZeneca (LON:AZN) Receives "Buy" Rating from Berenberg BankBerenberg Bank reiterated a "buy" rating and set a GBX 140 ($1.75) price objective on shares of AstraZeneca in a report on Monday.January 7, 2025 | marketbeat.comBernstein Keeps Their Buy Rating on AstraZeneca (AZN)January 7, 2025 | markets.businessinsider.comAstraZeneca PLC (LON:AZN) Given Average Recommendation of "Moderate Buy" by BrokeragesAstraZeneca PLC (LON:AZN - Get Free Report) has received an average recommendation of "Moderate Buy" from the nine brokerages that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigJanuary 5, 2025 | marketbeat.comSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZenecaJanuary 4, 2025 | markets.businessinsider.comAstraZeneca call volume above normal and directionally bullishJanuary 2, 2025 | markets.businessinsider.comHutchmed announces NDA acceptance in China, payment from AstraZenecaJanuary 2, 2025 | msn.comAstraZeneca (AZN) Faces Securities Class Action After Reports of PRC Probe into Fraud and Corruption - Hagens BermanDecember 25, 2024 | markets.businessinsider.comAstraZeneca's Tagrisso Gets EU Approval For Unresectable EGFR-mutated Lung CancerDecember 23, 2024 | markets.businessinsider.comAstraZeneca PLC (LON:AZN) Receives Average Rating of "Moderate Buy" from AnalystsShares of AstraZeneca PLC (LON:AZN - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the nine research firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rDecember 11, 2024 | marketbeat.comTop Stock Reports for Chevron, AstraZeneca & Arista NetworksNovember 29, 2024 | msn.comAstraZeneca's (AZN) Overweight Rating Reiterated at JPMorgan Chase & Co.JPMorgan Chase & Co. reiterated an "overweight" rating and issued a £140 ($176.26) price objective on shares of AstraZeneca in a report on Friday.November 22, 2024 | marketbeat.comInsider Buying: AstraZeneca PLC (LON:AZN) Insider Buys 1,500 Shares of StockNovember 21, 2024 | insidertrades.comAstraZeneca PLC (LON:AZN) Receives Average Rating of "Moderate Buy" from BrokeragesAstraZeneca PLC (LON:AZN - Get Free Report) has been given a consensus rating of "Moderate Buy" by the nine brokerages that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy raNovember 16, 2024 | marketbeat.comAstraZeneca PLC (LON:AZN) Insider Pascal Soriot Buys 20,000 SharesNovember 16, 2024 | insidertrades.comInsider Buying: AstraZeneca PLC (LON:AZN) Insider Buys 20,000 Shares of StockAstraZeneca PLC (LON:AZN - Get Free Report) insider Pascal Soriot purchased 20,000 shares of the firm's stock in a transaction on Thursday, November 14th. The shares were acquired at an average price of £102.03 ($131.30) per share, with a total value of £2,040,600 ($2,625,916.87).November 15, 2024 | marketbeat.comAstraZeneca put volume heavy and directionally bearishNovember 15, 2024 | markets.businessinsider.comAstraZeneca: Overcoming Short-term Challenges with Robust Long-term PotentialNovember 14, 2024 | markets.businessinsider.comAstraZeneca lifts 2024 outlook after Q3 beat, doubles down on US investmentsNovember 13, 2024 | msn.comAstraZeneca PLC (NASDAQ:AZN) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | msn.comBarclays Keeps Their Buy Rating on AstraZeneca (AZN)November 13, 2024 | markets.businessinsider.comAstraZeneca reports Q3 core EPS $2.08, consensus $1.03November 12, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: AstraZeneca (AZN) and Neurogene (NGNE)November 12, 2024 | markets.businessinsider.comAstraZeneca to spend $3.5B to expand U.S. operationsNovember 12, 2024 | seekingalpha.comAstraZeneca/Amgen's Asthma Drug Aces Late-Stage Study In Patients With Chronic RhinosinusitisNovember 8, 2024 | finance.yahoo.comAstraZeneca (LON:AZN) Given Overweight Rating at JPMorgan Chase & Co.JPMorgan Chase & Co. reissued an "overweight" rating and set a £140 ($182.24) target price on shares of AstraZeneca in a research note on Thursday.November 7, 2024 | marketbeat.comAstraZeneca extends losses as Chinese probe widensNovember 6, 2024 | msn.comTop AstraZeneca Executives Caught in Expanding China Probe, Shares Slide FurtherNovember 6, 2024 | finance.yahoo.comTD Cowen Sticks to Their Buy Rating for AstraZeneca (AZN)November 6, 2024 | markets.businessinsider.comAstraZeneca Falls Most Since 2020 as China Probe Fears MountNovember 5, 2024 | finance.yahoo.comAstraZeneca sheds £15 billion of market cap as weight-loss-pill data underwhelms investorsNovember 5, 2024 | msn.comGoldman Sachs Reaffirms Their Buy Rating on AstraZeneca (AZN)November 5, 2024 | markets.businessinsider.comBarclays Reaffirms Their Buy Rating on AstraZeneca (AZN)November 5, 2024 | markets.businessinsider.comAstraZeneca Unveils Early Data From Chinese-Firm Partnered Oral Weight Loss DrugNovember 4, 2024 | msn.comAstraZeneca (AZN) Receives a Buy from J.P. MorganNovember 4, 2024 | markets.businessinsider.comAre Options Traders Betting on a Big Move in AstraZeneca (AZN) Stock?November 4, 2024 | msn.comMonopar Therapeutics Stock Jumps 4X, Inks Licensing Pact With AstraZeneca For Once Terminated Phase 3 Candidate For Rare Genetic DisorderOctober 25, 2024 | benzinga.comAstraZeneca PLC (LON:AZN) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of AstraZeneca PLC (LON:AZN - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the nine brokerages that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and siOctober 22, 2024 | marketbeat.comWith 72% ownership, AstraZeneca PLC (LON:AZN) boasts of strong institutional backingOctober 20, 2024 | finance.yahoo.comHere are the 2025 dividend forecasts for FTSE giants Unilever, GSK, and AstraZenecaOctober 14, 2024 | msn.comAstraZeneca PLC ADR remains steady Tuesday, underperforms marketOctober 9, 2024 | marketwatch.comAstraZeneca Seeks Expanded Use For Blood Cancer Drug Calquence, FDA Grants Priority ReviewOctober 3, 2024 | finance.yahoo.comIs AstraZeneca PLC (NASDAQ:AZN) The Top Global Stock To Buy Now?September 30, 2024 | finance.yahoo.comAstraZeneca PLC (LON:AZN) Given Consensus Recommendation of "Moderate Buy" by AnalystsAstraZeneca PLC (LON:AZN - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the nine ratings firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendSeptember 27, 2024 | marketbeat.comTop Stock Reports for Toyota, AstraZeneca & ChubbSeptember 27, 2024 | finance.yahoo.comAstraZeneca’s Market Position and Drug Pipeline Sustain Buy Rating Despite TB01 Trial ResultsSeptember 23, 2024 | markets.businessinsider.com Get AstraZeneca News Delivered to You Automatically Sign up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter. Email Address AZN Media Mentions By Week AZN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AZN News Sentiment▼0.540.44▲Average Medical News Sentiment AZN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AZN Articles This Week▼52▲AZN Articles Average Week Get AstraZeneca News Delivered to You Automatically Sign up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GSK News Ithaca Energy News HUTCHMED News Grainger News Indivior News Bloomsbury Publishing News Global Ports News India Capital Growth News Alpha Real Trust News Pharos Energy News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:AZN) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AstraZeneca PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share AstraZeneca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AZN Stock Alerts